Core - Flow Cytology

Denning, Stephen M.

Abstract

The current flow cytometry facilities are of two basic types: 1) instrument for conducting work with virus infected material and 2) those for work with normal cells. The instrument for live virus work is currently located in space assigned to the Duke Aids Program with the Cancer Center Isolation Facility (see map at the end of this section) and will eventually be moved to the BL-2* containment area in the newly constructed virus research facility. This instrument was purchased as part of the Duke ACTG and its primary function is related to analysis of clinical samples from protocol patients. All other related on AIDS research which does not require containment is currently performed on other instruments within the medical center as time becomes available. Due to the expansion of our efforts within the context of the Duke CFAR, we require an additional instrument. The research projects to be served by this core facility are described below.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Center Core Grants (P30)
• Project #: 5P30AI028662-05
• Application #: 3769354
• Support Year: 5
• Fiscal Year: 1993

Institution

• Name: Duke University
• DUNS #: 071723621
• City: Durham
• State: NC
• Country: United States
• Zip Code: 27705

Publications

Betts, Michael R; Exley, Barbara; Price, David A et al. (2005) Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 102:4512-7

Ferrari, Guido; Neal, Wesley; Ottinger, Janet et al. (2004) Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J Immunol 173:2126-33

Freel, Stephanie A; Fiscus, Susan A; Pilcher, Christopher D et al. (2003) Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS 17:2025-33

Szczech, L A; Edwards, L J; Sanders, L L et al. (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57:336-41

Bartlett, John A; Miralles, G Diego; Sevin, Anne D et al. (2002) Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res Hum Retroviruses 18:535-43

Szczech, Lynda Anne; Gange, Stephen J; van der Horst, Charles et al. (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61:195-202

Pilcher, C D; Shugars, D C; Fiscus, S A et al. (2001) HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 15:837-45

Johnston, A M; Valentine, M E; Ottinger, J et al. (2001) Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J 20:941-6

Tokunaga, K; Greenberg, M L; Morse, M A et al. (2001) Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 75:6776-85

Pilcher, C D; Eron Jr, J J; Vemazza, P L et al. (2001) Sexual transmission during the incubation period of primary HIV infection. JAMA 286:1713-4